Clinical Trial Update: Phase II Study of Celecoxib and Concurrent Radiotherapy in Stage II-III NSCLC [Phase 2]

View source ↗

Summary

Phase II study evaluating celecoxib with concurrent radiotherapy in stage II-III Non-small cell lung cancer has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Celecoxib (Celebrex) (celecoxib)

Snippet

Sponsor: Maastricht Radiation Oncology | Conditions: Non Small Cell Lung Carcinoma | Phase 2 | Status: COMPLETED